HIV/HCV Drug Litigation

Commonly-prescribed drugs manufactured by Gilead Sciences, Inc. for the treatment and prevention of HIV and HCV have been shown to produce toxic side effects such as kidney disease, kidney failure, bone mineral density loss, bones fractures, bone breaks, and other debilitating bone and kidney conditions.

These drugs include all TDF-based medication and combination pill Gilead manufactures:

  • Viread (tenofovir disoproxil fumarate, TDF)
  • Truvada (TDF and emtricitabine) (including when taken for PrEP)
  • Atripla  (TDF, efavirenz, and emtricitabine)
  • Complera (TDF, emtricitabine, and rilpivirine)
  • Stribild (TDF, elvitegravir, cobicistat, and emtricitabine)

pill-closeup-web

If you or a loved one developed serious bone or kidney issues after taking any of these TDF-based drugs, you may be entitled to significant financial compensation.

Gilead has made billions from selling HIV antiretroviral drugs containing highly toxic doses of tenofovir disoproxil fumarate (“TDF”), a compound that Gilead knew all along was toxic to patients’ kidneys and bones. Despite this knowledge, Gilead falsely promoted its TDF drugs as “extremely safe” miracle drugs. In addition to misleading physicians and patients about TDF’s toxicity, Gilead intentionally withheld a safer alternative design of its TDF drugs from the public. As a result, Gilead knowingly exposed thousands of HIV patients to greater risks of kidney and bone toxicity. Gilead must be held accountable for its wanton and willful misconduct.

Please keep in mind that legal actions are time-sensitive and subject to strict statutes of limitation. To explore your legal options, we invite you to schedule a complimentary, no-obligation case review with our team of experienced pharmaceutical litigators. Please call 877-274-4497 or complete the form on this page to speak to an attorney.